DuoNeb Inhalation Solution has been approved for the treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD) in patients who require more than one bronchodilator. This product combines two respiratory solutions, ipratropium bromide and albuterol sulfate, in a premixed, premeasured, unit-dose vial for nebulization. With this formulation, there is no need for patients to dilute or mix solutions, and advantages may include faster treatment time and a reduced chance of medication error.
COPD includes emphysema and chronic bronchitis -- diseases that are characterized by airflow obstruction. According to the World Health Organization, COPD will be the third most common cause of death worldwide by 2020. The quality of life for a person suffering from COPD diminishes as the disease progresses. Current treatment is tailored to the severity of the disease and may include bronchodilators, antibiotics and exercise to strengthen muscles.
Results of an 863-subject trial demonstrated that DuoNeb improved bronchodilation over albuterol alone by 24% and over ipratropium alone by 37%, with no increased safety risk.
Adverse reactions reported with DuoNeb include (but are not limited to) the following:
Caution is advised for patients with the following conditions:
Albuterol sulfate administration, as well as the co-administration of DuoNeb and other sympathomimetic agents, may result in significant cardiovascular effects.
Albuterol is a beta2-adrenergic bronchodilator. Ipratropium bromide, also a bronchodilator, blocks the physiologic action of acetylcholine.
If you would like further information on COPD, please visit the National Library of Medicine.